Establishment, Maintenance, and Performance of the Cooperative Osteosarcoma Study Group (COSS)

Author:

Bielack Stefan S.12ORCID,Kager Leo3,Kühne Thomas4ORCID,Langer Thorsten5ORCID,Reichardt Peter6,Blattmann Claudia1ORCID,Kevric Matthias1,Mettmann Vanessa1,Sorg Benjamin1,Hecker-Nolting Stefanie1

Affiliation:

1. Cooperative Osteosarcoma Study Group, Pediatrics 5 (Oncology, Hematology, Immunology), Center for Pediatric, Adolescent and Women’s Medicine, Stuttgart Cancer Center, Klinikum Stuttgart—Olgahospital, 70174 Stuttgart, Germany

2. Klinik für Kinder- und Jugendmedizin, Pädiatrische Hämatologie und Onkologie, Universitätsklinikum Münster, 48149 Münster, Germany

3. St. Anna Kinderspital, University Hospital for Pediatric and Adolescent Medicine of the Medical University, and St. Anna Children’s Cancer Research Institute (CCRI), 1090 Vienna, Austria

4. Department of Pediatric Oncology/Hematology, Pediatric University Hospital Basel, CH-4031 Basel, Switzerland

5. Hospital for Pediatric and Adolesent Medicine, Pediatric Hematology and Oncology, Rheumatology and Immunology, Universitity Hospital Schleswig-Holstein, Campus Kiel, 24105 Kiel, Germany

6. Onkologie und Palliativmedizin, Helios Klinikum Berlin-Buch, 13125 Berlin, Germany

Abstract

Introduction: Osteosarcoma treatment has benefitted greatly from collaborative research. This paper describes the history and accomplishments of the Cooperative Osteosarcoma Study Group (COSS), mainly dedicated to clinical questions, as well as remaining challenges. Materials and Methods: Narrative review of over four decades of uninterrupted collaboration within the multi-national German–Austrian–Swiss COSS group. Results: Since its very first prospective osteosarcoma trial starting in 1977, COSS has continuously been able to provide high-level evidence on various tumor- and treatment-related questions. This includes both the cohort of patients enrolled into prospective trials as well as those patients excluded from them for various reasons, followed in a prospective registry. Well over one hundred disease-related publications attest to the group’s impact on the field. Despite these accomplishments, challenging problems remain. Discussion: Collaborative research within a multi-national study group resulted in better definitions of important aspects of the most common bone tumor, osteosarcoma, and its treatments. Important challenges continue to persist.

Publisher

MDPI AG

Subject

Cancer Research,Oncology

Reference102 articles.

1. Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma;Jaffe;N. Engl. J. Med.,1974

2. Amputation and adriamycin in primary osteosarcoma;Cortes;N. Engl. J. Med.,1974

3. High-dose methotrexate with citrovorum factor rescue and adriamycin in childhood osteogenic sarcoma;Rosen;Cancer,1974

4. Supplementary antiblastic polychemotherapy in localized malignant bone tumors. I. Ewing’s sarcoma and osteosarcoma;Bacci;Chir. Organi Mov.,1975

5. Primary osteogenic sarcoma: The rationale for preoperative chemotherapy and delayed surgery;Rosen;Cancer,1979

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3